Nociceptin/Orphanin FQ Peptide (NOP) Receptor Agonists as Novel Analgesics in Pain Medicine

Chronic pain is a major cause of disability worldwide, impacting around 20% of adults globally. Conventional mu-opioid peptide (MOP) receptor agonists provide effective analgesia; however, their prolonged use is restricted by severe dose-limiting toxicities such as opioid-induced respiratory depression, analgesic tolerance, hyperalgesia, physical dependence, and addiction. The goal of this narrative literature review was to compile the available data on NOP receptor-targeted analgesics, with a focus on dual NOP/MOP agonists and cebranopadol. The pharmacological mechanisms, preclinical and clinical evidence, safety profile, and potential therapeutic role in pain management were all highlighted. The nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor system has been identified as a new pathway for managing pain through mechanisms that differ from those of classical opioid signaling. The NOP receptor is a Class A G-protein-coupled receptor (GPCR) that preferentially couples to inhibitory G(i/o) proteins. Upon activation, it suppresses adenylyl cyclase activity, lowers intracellular cyclic adenosine monophosphate (cAMP) levels, blocks voltage-gated calcium channels, and activates G-protein-gated inwardly rectifying potassium channels, thereby hyperpolarizing neurons and decreasing excitatory neurotransmitter release. NOP receptors are anatomically distributed throughout the peripheral and central nervous systems, including primary afferent sensory neurons, dorsal root ganglia, spinal dorsal horn, periaqueductal gray, rostral ventromedial medulla, central amygdala, ventral tegmental area, and nucleus accumbens. NOP activation via these pathways offers significant pain relief in acute nociception, as well as in chronic inflammatory and neuropathic pain conditions. Supraspinal activation of NOP within the mesocorticolimbic pathway influences the emotional aspect of pain by reducing corticotropin-releasing factor signaling and decreasing mesolimbic dopamine release. NOP agonism effectively provides analgesia while also attenuating drug reward and reinforcement. The development of pharmaceuticals utilizing NOP agonism has progressed from endogenous peptide analogues to selective non-peptide agonists, and more recently to bifunctional NOP/MOP (dual NMR) agonists, such as the dual NOP/MOP agonist cebranopadol, which has passed Phase I–III clinical testing. There are still significant questions about long-term safety, comparative efficacy, and the interpretation of unpublished or preliminary Phase III results, despite the fact that available clinical trials indicate analgesic efficacy with perhaps decreased respiratory and abuse-related effects. This drug achieves equianalgesic efficacy through potent dual NOP/MOP activation while significantly reducing the risk of respiratory depression and drug-liking. However, clinical translation of NOP receptor agonism is hindered by several challenges, including supraspinal pronociceptive paradoxes, species-specific pharmacology, dose-dependent sedation, and regulatory complexities associated with mixed-mechanism ligands. NOP-targeted therapies represent a promising approach for the development of next-generation, opioid-sparing analgesics in pain medicine.